Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BETAPACE®/BETAPACE AF safely and effectively. See full prescribing information for BETAPACE/BETAPACE AF. BETAPACE (sotalol hydrochloride) tablets, for oral use Initial U.S. Approval: 1992 BETAPACE AF (sotalol hydrochloride) tablets, for oral use Initial U.S. Approval: 1992
Medication labelWhy this: Advisory · dailymed-prescription
Betapace/Betapace AF is indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (VT). Limitation of Use: Betapace/Betapace AF has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. Betapace/Betapace AF is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of AFIB/AFL) in patients with highly symptomatic AFIB/AFL who are currently in sinus rhythm. Limitation of Use: Because Betapace/Betapace AF can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom AFIB/AFL is highly symptomatic. Patients with paroxysmal AFIB that is easily reversed (by Valsalva maneuver, for example) should usually not be given Betapace/Betapace AF.
- generic_name
- sotalol hydrochloride
- product_names
- sotalol hydrochloride
- ndc
- 83107-005, 83107-006, 83107-007, 83107-008, 83107-009, 83107-010, 83107-005-10, 83107-006-10, 83107-007-10, 83107-008-60, 83107-009-60, 83107-010-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en